Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY) Sees Significant Increase in Short Interest

Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY) was the target of a significant increase in short interest in the month of July. As of July 15th, there was short interest totaling 9,026 shares, an increase of 319.0% from the June 30th total of 2,154 shares. Based on an average trading volume of 90,174 shares, the short-interest ratio is presently 0.1 days.

Ono Pharmaceutical Price Performance

OPHLY stock opened at $4.93 on Friday. Ono Pharmaceutical has a 52-week low of $3.55 and a 52-week high of $5.75. The company’s 50-day simple moving average is $4.84 and its 200-day simple moving average is $5.00.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and marketing of prescription drugs and diagnostics. Headquartered in Osaka, the company traces its origins to the early 18th century and has grown into a global specialty?pharmaceutical firm. Its product portfolio spans oncology, immunology, allergy and inflammatory diseases, with a notable focus on novel immunotherapies.

In oncology, Ono Pharmaceutical is best known for co?developing and commercializing nivolumab (Opdivo), an anti–PD?1 immune checkpoint inhibitor developed in partnership with Bristol?Myers Squibb.